Protalix sachliche Diskussionen (Seite 4)
eröffnet am 15.09.09 23:58:33 von
neuester Beitrag 18.05.23 08:06:20 von
neuester Beitrag 18.05.23 08:06:20 von
Beiträge: 99
ID: 1.153.048
ID: 1.153.048
Aufrufe heute: 8
Gesamt: 10.610
Gesamt: 10.610
Aktive User: 0
ISIN: US74365A3095 · WKN: A2PWSL · Symbol: PBDA
1,0730
EUR
-1,38 %
-0,0150 EUR
Letzter Kurs 17.04.24 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 0,9300 | +54,46 | |
| 2,3300 | +35,61 | |
| 2,4700 | +33,51 | |
| 1,9100 | +29,93 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,3000 | -20,96 | |
| 1,4300 | -24,34 | |
| 3,7920 | -25,57 | |
| 2,2000 | -31,25 | |
| 2,0900 | -40,52 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 67.817.828 von Opa_Klaus am 14.04.21 19:52:58
Mal sehen, ein paar Stunden bis dahin.
Zitat von Opa_Klaus: Wäre schön, wenn zum Börsenschluss die 6 vor dem Komma Bestand hat.
Mal sehen, ein paar Stunden bis dahin.
Wäre schön, wenn zum Börsenschluss die 6 vor dem Komma Bestand hat. 
Antwort auf Beitrag Nr.: 67.716.601 von bcgk am 06.04.21 16:51:03INDUSTRY INSIGHT
https://www.grandviewresearch.com/industry-analysis/fabry-di…
https://www.grandviewresearch.com/industry-analysis/fabry-di…
PDUFA am 27. April
MK $156m
Kauf @ $5
MK $156m
Kauf @ $5
Dieser Autor hier ist extrem optimistisch gestimmt, das ist mir fast schon zu viel:
PLX - Investors Happy That April 27, 2021 PDUFA Date Was Not Delayed Per March 30, 2021 4Q 2020 Financial/Corporate Update. Potential 300% Gainer In April
• Protalix management expects its Fabry drug approval as scheduled on April 27 PDUFA date per recent CEO comments and publications. Downside is minimal with potential 300%+ on approval.
• March 30, 2021 4Q 2020 Earnings and Corporate update reflects that April 27, 2021 PDUFA date is unchanged lifting a major uncertainty and worry that a second delay could occur.
• Protalix is funded to 3Q 2023 with recent $40M equity raise at $4.6/share. Additionally, Protalix will receive up to $1 billion in milestones and 40% tiered royalties upon PRX-102 approval.
• The company’s Fast-Track-designated PRX-102 for Fabry disease PDUFA date has been set for April 27, 202. If approved, PRX-102 could become the market leader in the $4B/year Fabry market currently led by Sanofi's Fabrazyme and growing at a 10% CAGR. Protalix currently enjoys a BUY rating with a consensus $13/share price target. Insiders and institutions own about 50% of common shares. The resulting public float is about 15M shares.
• During the March 9, 2021 H. C. Wainwright presentation CEO Bashan commented that "very soon the $58M convertible debt will convert at $8.5/share" causing the company to become debt free with over $100M in cash. Now, assuming a 7M dilution at $8.5/share, the market cap at that time would be only $440M. I say "only" because with FDA approving PRX-102, the company would have 2 FDA approved drugs, a growing pipeline, and over $100M in cash. A realistic market cap based on those parameters and adding the almost $1B in milestones and up to 40% royalties from PRX-102 approval would be almost $2B or 10 times the current market cap.
https://seekingalpha.com/amp/instablog/50857529-johnsoriakno…
PLX - Investors Happy That April 27, 2021 PDUFA Date Was Not Delayed Per March 30, 2021 4Q 2020 Financial/Corporate Update. Potential 300% Gainer In April
• Protalix management expects its Fabry drug approval as scheduled on April 27 PDUFA date per recent CEO comments and publications. Downside is minimal with potential 300%+ on approval.
• March 30, 2021 4Q 2020 Earnings and Corporate update reflects that April 27, 2021 PDUFA date is unchanged lifting a major uncertainty and worry that a second delay could occur.
• Protalix is funded to 3Q 2023 with recent $40M equity raise at $4.6/share. Additionally, Protalix will receive up to $1 billion in milestones and 40% tiered royalties upon PRX-102 approval.
• The company’s Fast-Track-designated PRX-102 for Fabry disease PDUFA date has been set for April 27, 202. If approved, PRX-102 could become the market leader in the $4B/year Fabry market currently led by Sanofi's Fabrazyme and growing at a 10% CAGR. Protalix currently enjoys a BUY rating with a consensus $13/share price target. Insiders and institutions own about 50% of common shares. The resulting public float is about 15M shares.
• During the March 9, 2021 H. C. Wainwright presentation CEO Bashan commented that "very soon the $58M convertible debt will convert at $8.5/share" causing the company to become debt free with over $100M in cash. Now, assuming a 7M dilution at $8.5/share, the market cap at that time would be only $440M. I say "only" because with FDA approving PRX-102, the company would have 2 FDA approved drugs, a growing pipeline, and over $100M in cash. A realistic market cap based on those parameters and adding the almost $1B in milestones and up to 40% royalties from PRX-102 approval would be almost $2B or 10 times the current market cap.
https://seekingalpha.com/amp/instablog/50857529-johnsoriakno…
Trading Spotlight
Die Analysten halten die Aktie für unterbewertet:
Protalix BioTherapeutics – Consensus Indicates Potential 179.6% Upside
Protalix BioTherapeutics with ticker code (PLX) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 15 and 11 with the average target price sitting at 13. Now with the previous closing price of 4.65 this now indicates there is a potential upside of 179.6%.
https://www.directorstalkinterviews.com/protalix-biotherapeu…
Antwort auf Beitrag Nr.: 67.163.712 von wirdschongutgehen am 23.02.21 18:48:53Guter Zeitpunkt woher den Tipp bekommen😁😁
Wer wissen will wohin der Kurs führen kann der sollte Biocryst nach der Zulassung abschauen 3 -> 12!!!
Die Analysten halten Protalix BioTherapeutics Inc für unterbewertet:
Protalix BioTherapeutics – Consensus Indicates Potential 169.7% Upside
Protalix BioTherapeutics found using ticker (PLX) now have 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 15 and 11 with the average target price sitting at 13. Given that the stocks previous close was at 4.82 this indicates there is a potential upside of 169.7%.
https://www.directorstalkinterviews.com/protalix-biotherapeu…
Durchsuchen
